Al­most 40 years af­ter an ad­com­m's warn­ing: FDA and spon­sors with­draw ap­proval for an­a­bol­ic steroid

The FDA an­nounced that it’s with­draw­ing the ap­proval of Gem­i­ni Lab­o­ra­to­ries’ an­a­bol­ic steroid Oxan­drin (oxan­drolone) and four gener­ic ver­sions, a decades-old treat­ment once in­di­cat­ed for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.